Leukemia
If it’s your first time on this website, please read the disclaimer section.
Jul 13 – Jul 20, 2026
Development and External Validation of a Transcriptome-Based Multivariable Prediction Model for Treatment-Free Remission in Chronic Myeloid Leukemia.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This study aimed to develop and externally validate a transcriptome-based multivariable model predicting treatment-free remission (TFR) in chronic myeloid leukemia (CML) patients after tyrosine kinase inhibitor (TKI) discontinuation. Researchers profiled peripheral blood transcriptomes from 96 CML patients to identify a 50-gene signature, which was then validated in an independent cohort of 70 patients. The signature effectively discriminated patients achieving sustained 2-year TFR from those relapsing, showing an AUROC of 0.83 in the training cohort and 0.71 in the external validation cohort. This predictive model offers a robust biomarker to guide TKI discontinuation decisions, potentially improving CML patient management and quality of life by identifying candidates for successful treatment cessation.
10.1200/JCO-25-02948
Jun 29 – Jul 06, 2026
A genomic and epigenomic lens into the biology of acute lymphoblastic leukaemia.
NAT REV CANCER · Q1 JOURNAL - RANK #3/326TOP-TIER
This review examines recent advances in genomic and epigenomic profiling of acute lymphoblastic leukaemia (ALL) to identify molecular subtypes and genetic drivers. Research has identified over 40 molecular subtypes of B-cell precursor ALL defined by distinct transcriptional programs, while also uncovering biologically defined T-cell ALL subtypes. These genomic insights inform risk stratification and the use of targeted therapies for kinase-activating alterations, though clonal evolution and epigenetic reprogramming continue to drive treatment resistance. Integrating these molecular findings into clinical practice enhances diagnostic classification and therapeutic outcomes by addressing the genetic heterogeneity inherent in ALL progression.
10.1038/s41568-026-00951-x
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This study developed and validated the PRISM prognostic model for risk stratification in 2,092 adults with newly diagnosed Acute Myeloid Leukemia (AML) treated with hypomethylating agents plus venetoclax (HMA + VEN), using a multinational dataset and robust statistical modeling. PRISM integrated 17 clinical and genomic variables, demonstrating a linear association with overall survival. Key findings showed PRISM-3 stratified survival consistently, with median OS ranging from 25.1-28.8 months for low risk to 5.8-6.7 months for high risk (p < .001), significantly outperforming the 4-gene classifier (C-index 0.63-0.65 vs 0.59-0.61; p < .05). This model directly enhances cancer prognosis for AML patients, supporting individualized, risk-adapted clinical decision-making and improving patient management in oncology.
10.1200/JCO-26-00347
Jun 08 – Jun 15, 2026
The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE).
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This phase 1-2 study (SAVE) evaluated an all-oral regimen of revumenib, decitabine/cedazuridine, and venetoclax in 42 patients with relapsed/refractory AML (median age 40 years, 52% prior venetoclax). The composite complete remission (CRc) rate was 71%, with 60% achieving CR/CRh and 80% of those attaining measurable residual disease negativity. Median duration of CR/CRh was 10.5 months overall, with differentiation syndrome in 10% (grade 3 in 5%) and febrile neutropenia in 36%. For clinicians focused on cancer, this provides promising efficacy and safety data for a novel oral combination targeting menin-KMT2A-dependent AML, though it is specific to molecular subtypes and not broadly applicable to all cancer types.
10.1200/JCO-26-01159
All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia.
NEW ENGL J MED · Q1 JOURNAL - RANK #2/332TOP-TIER
This phase 1-2, open-label trial evaluated an all-oral decitabine-cedazuridine plus venetoclax regimen for newly diagnosed Acute Myeloid Leukemia (AML) patients aged ≥75 or ineligible for intensive chemotherapy. No drug-drug interactions were observed. In phase 2b, 47% of patients achieved a complete response (CR), and 63% achieved CR or CR with incomplete hematologic recovery (CRi), with a median overall survival of 15.5 months. This all-oral regimen offers a less burdensome, viable treatment alternative for a vulnerable cancer patient population, directly addressing a critical need in AML management and potentially improving accessibility and quality of life.
10.1056/NEJMoa2510223
May 18 – May 25, 2026
CRISPR-Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial.
NAT MED · Q1 JOURNAL - RANK #1/195TOP-TIER
This phase 1/2a open-label study investigated CRISPR-Cas9 CD33-deleted allogeneic HCT (trem-cel) followed by gemtuzumab ozogamicin (GO) maintenance in 30 high-risk AML/MDS patients. All patients achieved neutrophil engraftment by day 28 (median 10 days, 95% CI: 9-10). GO maintenance was safely tolerated up to 2 mg/m² in 19 patients, with no prolonged high-grade cytopenias observed. This approach demonstrates safe, rapid engraftment and enables CD33-targeted maintenance without significant hematologic toxicity, offering a promising strategy for high-risk hematologic cancer patients.
10.1038/s41591-026-04362-1
Apr 27 – May 04, 2026
Adult T-Cell Leukemia/Lymphoma and Targeted Maternal Screening.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This population-based study analyzed US cancer registries (2005-2022) to estimate Adult T-cell leukemia/lymphoma (ATLL) incidence. It identified 3228 ATLL cases, finding non-Hispanic Caribbean-born US residents had an incidence rate of 14.1 per million, significantly higher than US/Canada-born populations (0.4 per million; IRR, 32.0), with rates peaking at 33.7 per million. Five-year survival was poor (23.8%), lowest among Caribbean-born individuals, highlighting a critical health disparity for this aggressive cancer. These findings identify early-life HTLV-1 infection as an actionable target for cancer prevention through maternal screening, with implications for reducing future ATLL burden.
10.1001/jamaoncol.2026.0859
Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This randomized, placebo-controlled trial evaluated whether prophylactic B-cell depletion with obinutuzumab could prevent corticosteroid-requiring chronic graft-versus-host disease (cGVHD) in 178 allogeneic transplant recipients. Obinutuzumab significantly reduced the 1-year incidence of steroid-requiring cGVHD to 13.3% compared to 35.2% in the placebo group (p=0.0005) and improved 2-year immunosuppression-free, relapse-free survival (48% vs. 34%). While the study focuses on a post-transplant complication, the findings are highly relevant for clinicians managing hematologic malignancies where cGVHD remains a major barrier to successful recovery. These results suggest that early B-cell depletion is an effective strategy for reducing morbidity and improving long-term outcomes in high-risk cancer patients undergoing transplantation.
10.1200/JCO-25-03104
Safety and Clinical Outcomes of Pooled Donor, Nonengrafting Expanded Progenitor Cells in Single-Unit Cord Blood Transplantation.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This phase II study investigated the safety and efficacy of adding dilanubicel, an expanded progenitor cell product, to single-unit cord blood transplantation (CBT) in 28 patients with hematologic malignancies. All patients achieved neutrophil engraftment (median 18 days) and platelet engraftment (median 31 days), with no grade 3-4 acute or chronic GVHD observed. At a median 1.4-year follow-up, 27 patients remained alive and disease-free, demonstrating faster hematopoietic recovery and lower severe acute GVHD compared to standard CBT. These findings suggest dilanubicel improves the safety and outcomes of a critical curative treatment for cancer patients, supporting further investigation.
10.1200/JCO-25-02510
Apr 20 – Apr 27, 2026
Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This expert opinion paper reviews the diagnostic and therapeutic management of various hematologic malignancies diagnosed during pregnancy, addressing the increasing global incidence in this population. The authors evaluate the safety and efficacy of diagnostic modalities and treatment options, including chemotherapy, radiation therapy, and immunotherapy, for conditions such as acute leukemia and lymphomas. It provides clinical guidance on balancing maternal oncological care with fetal safety, emphasizing that more women are now receiving adequate treatment without compromising pregnancy outcomes. The findings suggest that multidisciplinary approaches allow for expanded treatment possibilities, though specific numerical survival data were not provided in this qualitative expert consensus.
10.1200/JCO-25-02351